

# Arix Bioscience PLC

14:10 21 Nov 2019

## Arix Bioscience portfolio company Harpoon agrees US\$2.4bn deal with Abbvie

Arix Bioscience PLC (LON:ARIX) portfolio company Harpoon Therapeutics (NASDAQ:HARP) has granted pharma giant Abbvie (NYSE:ABBV) an exclusive option over the rights to a treatment for a type of blood cancer.

The drug, HPN217, uses Harpoon's Tri-specific T cell Activating Construct (TriTAC) technology to target BCMA, a biomarker associated with multiple myeloma cancer.

This latest agreement builds on a collaboration deal signed in 2017 and also gives Abbvie exclusive rights to develop and market two new TriTAC molecules plus an option to select up to four additional targets.

For each of the targets, Harpoon will receive a milestone payment of \$310mln each upfront plus royalties on global sales.

Abbvie already has a drug in development for multiple myeloma but its progress has dogged by safety issues.

Harpoon will receive US\$50mln upfront for the option over HPN217 and a further US\$50mln when the first patient is treated in a clinical trial, though the licence and option agreement represents a potential transaction value of up to \$510mln including royalties.

TriTacs are a group of T cell engagers that encourage the body's own immune system to target both solid tumours and hematologic malignancies.

Arix shares rose 2% to 113.5p.

**Price:** 96

**Market Cap:** £130.13 m

### Share Information

**Code:** ARIX

**Listing:** LSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>177.5</b>	<b>95.15</b>

**Sector:** **Medical technology & services**

**Website:** **arixbioscience.com**

### Company Synopsis:

*Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients.*

**action@proactiveinvestors.com**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability,

value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).